Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC)

Colloids and Surfaces B: Biointerfaces

Volumn 153, Issue , 2017, Pages 208-219

  Godugu, Chandraiah ^a,b   Doddapaneni, Ravi ^a,c   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer; Bioavailability; Honokiol; Nanomicellar formulation; TNBC

Indexed keywords

ANIMALS; CELL DEATH; CHEMOTHERAPY; DISEASES; FINITE DIFFERENCE METHOD; TUMORS;

ANTICANCER; BIOAVAILABILITY; HONOKIOL; NANOMICELLAR FORMULATION; TNBC;

BIOCHEMISTRY;

HONOKIOL; PACLITAXEL; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; LIGNAN; MICELLE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; WOUND HEALING; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; C57BL MOUSE; CACO-2 CELL LINE; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICELLE; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; CACO-2 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIGNANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICELLES; NANOPARTICLES; PARTICLE SIZE; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85013784542     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2017.01.038     Document Type: Article

References (52)

1. [1] Jamdade, V.S., et al. Therapeutic targets of triple-negative breast cancer: a review. Br. J. Pharmacol. 172:17 (2015), 4228–4237.
2. [2] Foulkes, W.D., Smith, I.E., Reis-Filho, J.S., Triple-negative breast cancer. New Engl. J. Med. 363:20 (2010), 1938–1948.
3. [3] Prat, A., et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18:2 (2013), 123–133.
4. [4] Godugu, C., et al. Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One, 9(3), 2014, e89919.
5. [5] Cragg, G.M., Grothaus, P.G., Newman, D.J., Impact of Natural products on developing new anti-cancer agents†. Chem. Rev. 109:7 (2009), 3012–3043.
6. [6] Gullett, N.P., et al. Cancer prevention with natural compounds. Seminars in Oncology, 2010, Elsevier.
7. [7] Amin, A.R., et al. Perspectives for cancer prevention with natural compounds. J. Clin. Oncol. 27:16 (2009), 2712–2725.
8. [8] Fried, L.E., Arbiser, J.L., Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid. Redox Signal. 11:5 (2009), 1139–1148.
9. [9] Pillai, V.B., et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat. Commun., 6, 2015.
10. [10] Kuribara, H., Stavinoha, W.B., Maruyama, Y., Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepam‐like side‐effects in mice. J. Pharm. Pharmacol. 51:1 (1999), 97–103.
11. [11] Chen, Y.J., et al. Honokiol, a low molecular weight natural product, prevents inflammatory response and cartilage matrix degradation in human osteoarthritis chondrocytes. J. Orthop. Res. 32:4 (2014), 573–580.
12. [12] Yu, Y., et al. Honokiol protects against renal ischemia/reperfusion injury via the suppression of oxidative stress, iNOS, inflammation and STAT3 in rats. Mol. Med. Rep. 13:2 (2016), 1353–1360.
13. [13] Arora, S.et al., Honokiol: a novel natural agent for cancer prevention and therapy. Curr. Mol. Med., 12(10), 2012, 1244.
14. [14] Liu, H., et al. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur. J. Pharmacol. 591:1 (2008), 43–51.
15. [15] Chen, F., et al. Honokiol: a potent chemotherapy candidate for human colorectal carcinoma. World J. Gastroenterol.: WJG 10:23 (2004), 3459–3463.
16. [16] Jeong, J.J., et al. Honokiol exerts an anticancer effect in T98G human glioblastoma cells through the induction of apoptosis and the regulation of adhesion molecules. Int. J. Oncol. 41:4 (2012), 1358–1364.
17. [17] Battle, T.E., Arbiser, J., Frank, D.A., The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 106:2 (2005), 690–697.
18. [18] Hahm, E.-R., Singh, S.V., Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol. Cancer Ther. 6:10 (2007), 2686–2695.
19. [19] Yang, S.-E., et al. Down-modulation of Bcl-X L, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem. Pharmacol. 63:9 (2002), 1641–1651.
20. [20] Li, Z., et al. Honokiol: a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur. J. Obstet. Gynecol. Reprod. Biol. 140:1 (2008), 95–102.
21. [21] Ahn, K.S., et al. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-κB activation pathway. Mol. Cancer Res. 4:9 (2006), 621–633.
22. [22] Hu, J., et al. Liposomal honokiol: a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity. Exp. Mol. Med. 40:6 (2008), 617–628.
23. [23] Zheng, X., et al. A novel transdermal honokiol formulation based on Pluronic F127 copolymer. Drug Deliv. 17:3 (2010), 138–144.
24. [24] Patel, K., et al. Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple-negative Breast cancer. J. Pharm. Sci. 104:12 (2015), 4417–4426.
25. [25] Godugu, C., et al. Novel gefitinib formulation with improved oral bioavailability in treatment of A431 skin carcinoma. Pharm. Res. 33:1 (2016), 137–154.
26. [26] Godugu, C., et al. Novel Diindolylmethane derivatives based NLC formulations to improve the oral Bioavailability and anticancer effects in Triple Negative Breast Cancer. Eur. J. Pharm. Biopharm., 2016.
27. [27] Mi, Y., Liu, Y., Feng, S.-S., Formulation of docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycolsuccinate 2000 (Vitamin E TPGS 2k) micelles for targeted and synergistic chemotherapy. Biomaterials 32:16 (2011), 4058–4066.
28. [28] Tsai, T.-H., et al. Pharmacokinetics of honokiol after intravenous administration in rats assessed using high performance liquid chromatography. J. Chromatogr. B: Biomed. Sci. Appl. 655:1 (1994), 41–45.
29. [29] Reddy, D.R.et al., Natural flavonoids silymarin and quercetin improve the brain distribution of co-administered P-gp substrate drugs. SpringerPlus, 5(1), 2016, 1618.
30. [30] Patel, A.R., et al. Evaluation of spray BIO-Max DIM-P in dogs for oral bioavailability and in nu/nu mice bearing orthotopic/metastatic lung tumor models for anticancer activity. Pharm. Res. 32:7 (2015), 2292–2300.
31. [31] Godugu, C., et al. Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J. Controll. Release 172:1 (2013), 86–95.
32. [32] Kumar, G.S., et al. Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy. Chem. Biol. Interactions 223 (2014), 125–133.
33. [33] Gluz, O., et al. Triple-negative breast cancer—current status and future directions. Ann. Oncol., 2009, 2016, pmdp492.
34. [34] Zheng, X., et al. Preparation of MPEG–PLA nanoparticle for honokiol delivery in vitro. Int. J. Pharm. 386:1 (2010), 262–267.
35. [35] Han, M., et al. Honokiol nanosuspensions: preparation, increased oral bioavailability and dramatically enhanced biodistribution in the cardio-cerebro-vascular system. Colloids Surf. B: Biointerfaces 116 (2014), 114–120.
36. [36] Li, X., et al. Sirolimus-loaded polymeric micelles with honokiol for oral delivery. J. Pharm. Pharmacol. 67:12 (2015), 1663–1672.
37. [37] Ding, W., et al. Co-delivery of honokiol, a constituent of Magnolia species, in a self-microemulsifying drug delivery system for improved oral transport of lipophilic sirolimus. Drug Deliv. 2015 (2016), 1–11.
38. [38] Gong, C., et al. Biodegradable self-assembled PEG–PCL–PEG micelles for hydrophobic honokiol delivery: I. Preparation and characterization. Nanotechnology, 21(21), 2010, 215103.
39. [39] Zhang, Y., et al. Encapsulation of honokiol into self-assembled pectin nanoparticles for drug delivery to HepG2 cells. Carbohydr. Polym. 133 (2015), 31–38.
40. [40] Singh, T., Prasad, R., Katiyar, S.K., Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo. Epigenetics 8:1 (2013), 54–65.
41. [41] Jin, S., et al. Improvement of oral bioavailability of glycyrrhizin by sodium deoxycholate/phospholipid-mixed nanomicelles. J. Drug Target. 20:7 (2012), 615–622.
42. [42] Wang, G., et al. Quercetin-loaded freeze-dried nanomicelles: improving absorption and anti-glioma efficiency in vitro and in vivo. J. Controll. Release, 2016.
43. [43] Ratnam, D.V., et al. A potential therapeutic strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q10: preparation and evaluation in streptozotocin induced diabetic rats. J. Biomed. Nanotechnol. 4:1 (2008), 33–43.
44. [44] Jain, A.K., et al. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model. Mol. Pharm. 8:4 (2011), 1140–1151.
45. [45] Doddapaneni, R., Patel, K., Chowdhury, N., Singh, M., Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Exp. Cell Res. 346:1 (2016), 65–73.
46. [46] Doddapaneni, R., Patel, K., Owaid, I.H., Singh, M., Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug Deliv. 23:4 (2016), 1232–1241.
47. [47] Patel, K., Doddapaneni, R., Chowdhury, N., Boakye, C.H., Behl, G., Singh, M., Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine (Lond). 11:11 (2016), 1377–1392.
48. [48] Patel, A.R., Doddapaneni, R., Andey, T., Wilson, H., Safe, S., Singh, M., Evaluation of self-emulsified DIM-14 in dogs for oral bioavailability and in Nu/nu mice bearing stem cell lung tumor models for anticancer activity. J. Control Release 10:213 (2015), 18–26.
49. [49] Patel, K., Doddapaneni, R., Sekar, V., Chowdhury, N., Singh, M., Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer. Mol. Pharm. 6 (2016), 2049–2058.
50. [50] Boakye, C.H., Doddapaneni, R., Shah, P.P., Patel, A.R., Godugu, C., Safe, S., Katiyar, S.K., Singh, M., Chemoprevention of skin cancer with 1,1-Bis (3'-indolyl)[HYPHEN]1-(aromatic) methane analog through induction of the orphan nuclear receptor, NR4A2 (Nurr1). PLoS One, 8, 2013, e69519.
51. [51] Arora, S.et al., Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS One, 6(6), 2011, e21573.
52. [52] Chen, F., et al. Honokiol: a potent chemotherapy candidate for human colorectal carcinoma. World J. Gastroenterol. 10:23 (2004), 3459–3463.